Soluble CD4 Inhibits Ebola Virus Infection by Targeting Endosomal Receptor-Binding Site

Authors

Leah Liu. Wang, University of Nebraska-Lincoln
Patrick Keiser, Boston University
Derek Yang, University of Pennsylvania
Javier G. Seravalli, University of Nebraska-Lincoln
J.J. Patten, Boston University
Brett Eaton, National Institute of Allergy and Infectious Diseases
Dirk Anderson, University of Nebraska-Lincoln
Yi Liu, University of Nebraska-Lincoln
Michael R. Holbrook, National Institute of Allergy and Infectious Diseases
Amos B. Smith Ⅲ, University of Pennsylvania
Robert A. Davey, Boston University
Shihua Xiang, University of Nebraska-LincolnFollow

Document Type

Article

Date of this Version

2025

Citation

iScience (2025) 28: 112573

doi: 10.1016/j.isci.2025.112573

Comments

Open access

License: CC BY 4.0

Abstract

Human CD4 (cluster of differentiation 4) is well known as the primary receptor for human immunodeficiency virus (HIV) entry into the cells. The virus binds to CD4 molecules to induce a conformational change in the viral glycoprotein (GP) gp120, which exposes the co-receptor binding site for coreceptors CCR5 or CXCR4. The co-receptor binding then leads to membrane fusion for viral entry. Since the CD4 molecule has a high affinity for gp120, soluble CD4 (sCD4) and CD4-mimetic small molecules (CD4mcs) have been extensively studied as potential inhibitors for HIV infection. Surprisingly, we have found that human sCD4 and some CD4mcs are able to inhibit Ebola virus (EBOV) infection. Evidence is provided that the compounds block viral entry by targeting the GP binding site for the endosomal receptor Niemann-Pick C1 (NPC1). This finding reveals virus-receptor binding similarities between two remote viruses (HIV and EBOV) and suggests new possibilities for EBOV entry inhibitors.